Takeda Moves Out From Licensing Agreement With Theravance Biopharma
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE:TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties' collaboration agreement with Theravance Biopharma Inc (NASDAQ:TBPH).
在其第一季度财报中， 武田制药 Co Ltd (NYSE: TAK) 表示，它同意停止进一步开发治疗术后胃肠道功能障碍的 TAK-954，并同意双方与之达成合作协议 Theravance 生物制药公司 （纳斯达克：TBPH）。
Takeda has discontinued 13 clinical-stage programs and discovery and pre-clinical efforts in adeno-associated virus (AAV) gene therapy.
武田已经停止了腺相关病毒 (AAV) 基因疗法的13个临床阶段项目、发现和临床前工作。
Also Read: Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues.
另请阅读：武田的22财年净利润增长了38％，但预计23财年收入将下降。
The companies entered into the agreement in June 2016, in which Theravance Biopharma received an upfront cash payment of $15 million and was eligible to receive $110 million in milestone payments.
两家公司于2016年6月签订协议，根据该协议，Theravance Biopharma获得了1500万美元的预付现金，并有资格获得1.1亿美元的里程碑式付款。
The investigational drug did not meet its endpoints in the Phase 2b study.
在2b期研究中，该研究药物未达到其终点。
Takeda also cut sibofimloc, a small molecule for Crohn's disease (post-operative and ileal-dominant), after the Phase 2a study did not meet its endpoints.
在2a期研究未达到终点之后，武田还切断了治疗克罗恩病（术后和回肠显性）的小分子sibofimloc。
From Phase 3, Takeda cut trials on four drugs already approved in other indications, namely the cancer drugs Ninlaro (ixazomib), Zejula (Niraparib), antiviral Livtencity (maribavir)and Takhzyro (lanadelumab), a hereditary angioedema drug.
从第三阶段开始，武田削减了对四种已经批准用于其他适应症的药物的试验，即抗癌药物Ninlaro（ixazomib）、Zejula（Niraparib）、抗病毒药物Livtencity（maribavir）和遗传性血管性水肿药物Takhzyro（lanadelumab）。
Price Action: TAK shares are down 5.15% at $16.11, and TBPH shares are down 4.27% at $10.98 on the last check Thursday.
价格走势： 在周四的最后一张支票中，TAK股价下跌5.15％，至16.11美元，TBPH股价下跌4.27％，至10.98美元。